• Samsung Biologics signed a KRW 434.32 billion (USD 324.8 million) drug manufacturing contract with an undisclosed global pharmaceutical company.
• The contract runs from Nov. 2, 2026, the signing date, through Dec. 31, 2031.
• The deal represents 9.53% of 2025 consolidated revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261103800043), on November 03, 2026, and is solely responsible for the information contained therein.